255 related articles for article (PubMed ID: 33232507)
1. Immune checkpoint inhibitor therapy-associated encephalitis: a case series and review of the literature.
Stuby J; Herren T; Schwegler Naumburger G; Papet C; Rudiger A
Swiss Med Wkly; 2020 Nov; 150():w20377. PubMed ID: 33232507
[TBL] [Abstract][Full Text] [Related]
2. Encephalitis Induced by Immune Checkpoint Inhibitors: A Systematic Review.
Velasco R; Villagrán M; Jové M; Simó M; Vilariño N; Alemany M; Palmero R; Martínez-Villacampa MM; Nadal E; Bruna J
JAMA Neurol; 2021 Jul; 78(7):864-873. PubMed ID: 33720308
[TBL] [Abstract][Full Text] [Related]
3. Nivolumab-induced seronegative encephalitis.
Cabral G; Ladeira F; Gil N
J Neuroimmunol; 2020 Oct; 347():577350. PubMed ID: 32768895
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab-ipilimumab combination therapy-induced seronegative encephalitis; rapid response to steroid plus intravenous immunoglobulin (IVIG) treatment.
Bir Yucel K; Sutcuoglu O; Yazıcı O; Yıldız Y; Şenol E; Uner A
J Oncol Pharm Pract; 2023 Apr; 29(3):760-763. PubMed ID: 35938177
[TBL] [Abstract][Full Text] [Related]
5. Encephalitis in a patient with hypopharynx cancer treated with immune checkpoint inhibitors and radiotherapy: a case report and review of the literature.
Kang Y; Zhen H; Ma N; Zhao H; Cao B
J Cancer Res Clin Oncol; 2023 Nov; 149(17):16239-16246. PubMed ID: 37676267
[TBL] [Abstract][Full Text] [Related]
6. Nivolumab induced encephalopathy in a man with metastatic renal cell cancer: a case report.
Kopecký J; Kubeček O; Geryk T; Slováčková B; Hoffmann P; Žiaran M; Priester P
J Med Case Rep; 2018 Sep; 12(1):262. PubMed ID: 30217214
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study.
Müller-Jensen L; Zierold S; Versluis JM; Boehmerle W; Huehnchen P; Endres M; Mohr R; Compter A; Blank CU; Hagenacker T; Meier F; Reinhardt L; Gesierich A; Salzmann M; Hassel JC; Ugurel S; Zimmer L; Banks P; Spain L; Soon JA; Enokida T; Tahara M; Kähler KC; Seggewiss-Bernhardt R; Harvey C; Long GV; Schöberl F; von Baumgarten L; Hundsberger T; Schlaak M; French LE; Knauss S; Heinzerling LM
Eur J Cancer; 2022 Nov; 175():224-235. PubMed ID: 36155116
[TBL] [Abstract][Full Text] [Related]
8. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.
Larkin J; Chmielowski B; Lao CD; Hodi FS; Sharfman W; Weber J; Suijkerbuijk KPM; Azevedo S; Li H; Reshef D; Avila A; Reardon DA
Oncologist; 2017 Jun; 22(6):709-718. PubMed ID: 28495807
[TBL] [Abstract][Full Text] [Related]
9. Glial fibrillary acidic protein (GFAP) associated autoimmune meningoencephalitis in a patient receiving nivolumab.
Kapadia RK; Ney DE; Hannan M; Farley M; Pastula DM; Piquet AL
J Neuroimmunol; 2020 Jul; 344():577259. PubMed ID: 32416558
[TBL] [Abstract][Full Text] [Related]
10. Encephalitis related to immunotherapy for lung cancer: Analysis of a multicenter cohort.
Sanchis-Borja M; Ricordel C; Chiappa AM; Hureaux J; Odier L; Jeannin G; Descourt R; Gervais R; Monnet I; Auliac JB; Chouaïd C
Lung Cancer; 2020 May; 143():36-39. PubMed ID: 32200139
[TBL] [Abstract][Full Text] [Related]
11. The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature.
Kumar V; Shinagare AB; Rennke HG; Ghai S; Lorch JH; Ott PA; Rahma OE
Oncologist; 2020 Jun; 25(6):505-514. PubMed ID: 32043699
[TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal Fluid Interleukin-6 in Immune Checkpoint Inhibitor-Induced Autoimmune Meningoencephalitis.
Mizukami T; Masuda T; Kimura N; Uchida H; Jikumaru M; Hanaoka T; Matsubara E
Tohoku J Exp Med; 2022 Sep; 258(2):159-165. PubMed ID: 36047134
[TBL] [Abstract][Full Text] [Related]
13. Central nervous system complications associated with immune checkpoint inhibitors.
Vogrig A; Muñiz-Castrillo S; Joubert B; Picard G; Rogemond V; Marchal C; Chiappa AM; Chanson E; Skowron F; Leblanc A; Ducray F; Honnorat J
J Neurol Neurosurg Psychiatry; 2020 Jul; 91(7):772-778. PubMed ID: 32312871
[TBL] [Abstract][Full Text] [Related]
14. Nivolumab-Associated Acute Demyelinating Encephalitis: A Case Report and Literature Review.
Zafar Z; Vogler C; Hudali T; Bhattarai M
Clin Med Res; 2019 Jun; 17(1-2):29-33. PubMed ID: 31160476
[TBL] [Abstract][Full Text] [Related]
15. Atezolizumab-associated encephalitis in metastatic lung adenocarcinoma: a case report.
Yamaguchi Y; Nagasawa H; Katagiri Y; Wada M
J Med Case Rep; 2020 Jul; 14(1):88. PubMed ID: 32620173
[TBL] [Abstract][Full Text] [Related]
16. A case of repetitive seizures following immune checkpoint inhibitor therapy as a feature of autoimmune encephalitis.
Takebayashi Y; Neshige S; Hayashi T; Aoki S; Ueno H; Iida K; Maruyama H
Epileptic Disord; 2021 Oct; 23(5):733-738. PubMed ID: 34519645
[TBL] [Abstract][Full Text] [Related]
17. Elevated Adenosine Deaminase Levels in the Cerebrospinal Fluid in Immune Checkpoint Inhibitor-induced Autoimmune Encephalitis.
Fujiwara S; Mimura N; Yoshimura H; Fujimoto D; Ito M; Mori R; Ito J; Tomii K; Kawamoto M; Kohara N
Intern Med; 2019 Oct; 58(19):2871-2874. PubMed ID: 31243206
[TBL] [Abstract][Full Text] [Related]
18. Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors.
Vogrig A; Fouret M; Joubert B; Picard G; Rogemond V; Pinto AL; Muñiz-Castrillo S; Roger M; Raimbourg J; Dayen C; Grignou L; Pallix-Guyot M; Lannoy J; Ducray F; Desestret V; Psimaras D; Honnorat J
Neurol Neuroimmunol Neuroinflamm; 2019 Nov; 6(6):. PubMed ID: 31454760
[TBL] [Abstract][Full Text] [Related]
19. Autoimmune Encephalitis following Checkpoint Inhibitor Therapy in a Patient with Metastatic Melanoma in Complete Remission.
Civardi G; Medioli A; Braghieri C; Ambroggi M; Immovilli P; Orsucci S; Contini P; Aronica G; Cavanna L
Medicina (Kaunas); 2024 Apr; 60(5):. PubMed ID: 38792910
[TBL] [Abstract][Full Text] [Related]
20. [A case of myopathy, myocarditis, and encephalitis with nonconvulsive status epileptics after immune checkpoint inhibitor therapy for ureter cancer].
Akazawa S; Otsuka Y; Hashimoto R; Matsumoto M; Yoneda Y; Kageyama Y
Rinsho Shinkeigaku; 2022 May; 62(5):395-398. PubMed ID: 35474290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
